Loading
Instead of separate screening programmes for a few cancers, assess every adult's overall cancer risk and offer blood tests, imaging and preventive treatment tuned to that risk, all inside one system that learns.
Screening today covers a handful of cancers with organ-specific programmes and reaches a fraction of eligible people. Multi-cancer early detection blood tests (NHS-Galleri, PATHFINDER 2) and polygenic, exposure and imaging-based risk models make a unified approach conceivable: every adult over 40 receives a risk profile, a personalised detection schedule, and where indicated interception (chemoprevention, vaccines, risk-reducing procedures), with all results feeding a national learning system that recalibrates the models. Overdiagnosis is controlled through molecular indolence classifiers and surveillance-first protocols.
Shares FAPI PET as the workup for MCED positives, Whole-body MRI, Early detection of cancer, Positive predictive value (PPV).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Positive predictive value (PPV).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Stage shift.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Positive predictive value (PPV).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Positive predictive value (PPV).
Shares Early detection of cancer, Galleri, Positive predictive value (PPV), Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Early detection of cancer, NHS-Galleri, Multi-cancer early detection (MCED).
Shares Early detection of cancer, Positive predictive value (PPV), Overdiagnosis and false alarms, The hardest cancers are found late.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/